Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15629800 | 0.83 | DRD2 (0.46) | CNR2HTR3ALSSDRD2 | |
| SCHEMBL10177690 | 0.80 | HTR2A (0.46) | HTR3ALSSESR2 | |
| SCHEMBL4461976 | 0.80 | HTR3A (0.43) | HTR3ALSSDRD2ESR2 | |
| SCHEMBL27392425 | 0.76 | HTR3A (0.40) | HTR3ALSSDRD2KDM1AMAOA | |
| SCHEMBL10032835 | 0.75 | FFAR4 (0.47) | — | |
| SCHEMBL435619 | 0.74 | HTR3A (0.59) | HTR3ALSSDRD2ESR2 | |
| SCHEMBL15611484 | 0.73 | ESR2 (0.41) | HTR3AKDM1AMAOAMAOBESR2 | |
| SCHEMBL10177557 | 0.73 | DRD2 (0.49) | HTR3ALSSDRD2KDM1AESR2 | |
| SCHEMBL1709507 | 0.72 | MEN1 (0.44) | — | |
| SCHEMBL5389925 | 0.70 | HTR3A (0.47) | HTR3ALSSDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751877-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751877-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160024088-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders | PFIZER INC. | 2016-01-28 | — | — | US | disclosed |
| US-9193726-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150072990-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders | PFIZER INC. | 2015-03-12 | — | — | US | disclosed |
| US-8916564-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140088111-A1 | Novel Bicyclic Pyridinones | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072990-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders | PRNP, SNCA, PSEN1 | CNR2 690/4885HTR3A 213/4885LSS 2584/4885 |
| US-20140088111-A1 | Novel Bicyclic Pyridinones | CYP2B6, CYP2D6, CYP2C19 | CNR2 298/4885HTR3A 400/4885LSS 260/4885 |
| US-20160024088-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders | PRNP, SNCA, PSEN1 | CNR2 690/4885HTR3A 213/4885LSS 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.